Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03830723
Other study ID # ovord
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 9, 2020
Est. completion date September 27, 2021

Study information

Verified date January 2022
Source Clinique Ovo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is intended for women undergoing their first cycle of 3 intrauterine inseminations. All 3 inseminations will be personalized by using algorithms to determine the dose of study medication.


Description:

Study medication dosage for the first insemination cycle will be based on the woman's age as well as her Anti-Mullerian Hormone (AMH) levels. Study medication dosage for the second and third insemination will depend on ovarian response (number of follicles) during previous insemination cycle and woman's age


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date September 27, 2021
Est. primary completion date January 20, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 42 Years
Eligibility Inclusion Criteria: - Women having consented to the study - Women followed at fertility center - First IUI cycle - Women between the ages of 18 to 42 inclusively at time of consent form signature - AMH < 35 pmol/L (4.9 ng/mL) in participants' file in the last 24 months - At least one permeable Fallopian tube confirmed by laparoscopy, hysterosalpingography (HSG), hysterosalpingosonography (HSSG) or one pregnancy in the last 3 years - Insemination with either partner or donor sperm - Male partner semen analysis considered adequate for IUI in accordance to the centre's standard practice - Menstrual cycles from 26 to 39 days - Presence of both ovaries Exclusion Criteria: - Unable to consent - Body weight >100 kg - AMH =35 pmol/L (4.9 ng/mL) in participants' file in the last 24 months - Severe malformation (unicornuate or bicornuate uterus) or uterine anomaly including fibroids = 5 cm - Uncontrolled thyroid or adrenal dysfunction - Pituitary tumour - Persistent ovarian cysts or enlargement not due to PCOS (Polycystic ovary syndrome) > 3 cm - Anovulatory women - Use of contraceptives in the last 3 months prior to start of stimulation - Diagnosis of hydrosalpinx - Malignancies - Breast pathology incompatible with gonadotropin stimulation - Hypersensitivity to follitropin delta or to any ingredient in the formulation - Addition of other infertility medication that can influence follicle stimulation and maturation such as growth hormone (GH)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Follitropin delta
Study medication doses during all 3 insemination will be personalized using a suggested algorithm

Locations

Country Name City State
Canada Clinique Ovo Montréal Quebec

Sponsors (1)

Lead Sponsor Collaborator
Clinique Ovo

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ovarian response Evaluate the dose-response Relationship of Rekovelle with respect to ovarian response in participants undergoing controlled ovarian stimulation for intrauterine insemination 1 year
Secondary Pregnancy rate Evaluate pregnancy rate 6-8 weeks after insemination by ultrasound 1 year
See also
  Status Clinical Trial Phase
Completed NCT03607409 - Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
Recruiting NCT02312076 - GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles Phase 4
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Completed NCT03287479 - Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®) N/A
Terminated NCT03522350 - Randomized Trial Comparing EmbryoScope With EmbryoScope+. N/A
Completed NCT04496284 - Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen N/A
Completed NCT03623659 - pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts N/A
Completed NCT03895099 - New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors Phase 3
Active, not recruiting NCT04142112 - Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation N/A
Completed NCT03152643 - Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer N/A
Recruiting NCT03683771 - Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
Recruiting NCT03161119 - Comparing Two Different Embryo Transfer Catheters N/A
Completed NCT04108039 - Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles. N/A
Completed NCT03678584 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA) N/A
Completed NCT03677492 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD) N/A
Completed NCT03678818 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA) N/A
Completed NCT03678610 - Handling Medium for ICSI With Ionomycin and Latrunculin A N/A
Completed NCT03678571 - Oocyte Vitrification Aided With Latrunculin A N/A
Completed NCT03678558 - Oocyte Vitrification Aided With Cytochalasin B N/A
Completed NCT03678597 - Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB) N/A